Highlights of ESC HF 2021 - AFFIRM-AHF-based multinational cost-effectiveness analysis of intravenous ferric carboxymaltose for the treatment of iron deficiency in an acute heart failure setting
Highlights of ESC HF 2021 - AFFIRM-AHF-based multinational cost-effectiveness analysis of intravenous ferric carboxymaltose for the treatment of iron deficiency in an acute heart failure setting

Highlights of ESC HF 2021 - AFFIRM-AHF-based multinational cost-effectiveness analysis of intravenous ferric carboxymaltose for the treatment of iron deficiency in an acute heart failure setting

1 pistes • 0 écoutes • 0 favoris

Highlights of ESC HF 2021 - AFFIRM-AHF-based multinational cost-effectiveness analysis of intravenous ferric carboxymaltose for the treatment of iron deficiency in an acute heart failure setting

Demms Dezzy

0:003:32
Knowledge
Highlights of ESC HF 2021 - AFFIRM-AHF-based multinational cost-effectiveness analysis of intravenous ferric carboxymaltose for the treatment of iron deficiency in an acute heart failure setting - Play Online Free | WowFM